Economy

Food Allergy Biotech Firm Lycia Jumps 32% After Upsized IPO

Lycia Therapeutics Inc. shares leapt 32% in its trading debut, after the biotechnology firm focused on treatments for allergies and autoimmune diseases raised $317.5 million in an upsized US initial public offering.